Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy

Study ID
STU 042013-080

Study Sites

  • Parkland Health & Hospital System

Contact
Allison Beaver
214/645-8788
ALLISON.BEAVER@UTSouthwestern.edu

Principal Investigator
Yair Lotan, M.D.

Official Title

Randomized Trial of Adjuvant Curcumin After Prostatectomy

Brief Overview

This is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free survival.

Description

This is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free survival in patients after radical prostatectomy compared to placebo

Eligibility

Inclusion Criteria:
- radical prostatectomy for adenocarcinoma of prostate
- pathologically confirmed T1-T3 disease
- no sign of lymph node or metastatic disease
- Eastern Cooperative Oncology Group(ECOG) status 0-2
- adequate renal and liver function
- no plan to receive adjuvant hormone or radiation therapy
- life expectancy of 3 years
Exclusion Criteria:
- must not have exceeded 3 months from time of surgery to enrollment into study
- T3b or T4 or node positive disease
- hormone therapy before surgery
- history of gallbladder problems or gallstones, or biliary obstruction
- radiation therapy as primary treatment after surgery
- antiplatelet or anticoagulant agents
- history of gastric or duodenal ulcers or hyperacidity syndromes